Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 8/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16201598 | 0.77 | LMNA (0.55) | MAPK1LMNAKMT2AF10F2 | |
| Hydrochloric Acid SCHEMBL1770731 | 0.76 | LMNA (0.54) | MAPK1LMNAKMT2AF10F2 | |
| SCHEMBL12124252 | 0.75 | ALDH1A1 (0.53) | LMNAKMT2AL3MBTL1 | |
| SCHEMBL5630030 | 0.75 | MAPK1 (0.63) | MAPK1LMNAKMT2AF10F2 | |
| SCHEMBL12124247 | 0.74 | ALDH1A1 (0.52) | LMNAKMT2AHPGDL3MBTL1 | |
| SCHEMBL13211868 | 0.74 | KMT2A (0.57) | LMNAKMT2ATSHR | |
| SCHEMBL6362178 | 0.73 | MAPK1 (0.69) | MAPK1LMNAKMT2AF10F2 | |
| SCHEMBL12124454 | 0.72 | ALDH1A1 (0.50) | LMNAKMT2AF10HPGDTSHR | |
| SCHEMBL3402914 | 0.72 | MAPK1 (0.46) | MAPK1LMNAKMT2AF10F2 | |
| SCHEMBL16556595 | 0.71 | MAPK1 (0.66) | MAPK1F10HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637479-B2 | Tartrate salt of 5-chloro-thiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxo-pyrrolidin-1-yl)-benzenesulfonylamino]-3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]amide | SANOFI (FR) | 2017-05-02 | — | — | US | disclosed |
| US-20160102082-A1 | TARTRATE SALT OF 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID [(S)-2-[METHYL-3-(2-OXO-PYRROLIDIN-1-YL)-BENZENESULFONYLAMINO]-3-(4-METHYL-PIPERAZIN-1-YL)-3-OXO-PROPYL]AMIDE | BEIJING COLLAB PHARM CO., LTD. (CN) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102082-A1 | TARTRATE SALT OF 5-CHLORO-THIOPHENE-2-CARBOXYLIC ACID [(S)-2-[METHYL-3-(2-OXO-PYRROLIDIN-1-YL)-BENZENESULFONYLAMINO]-3-(4-METHYL-PIPERAZIN-1-YL)-3-OXO-PROPYL]AMIDE | CPS1, ACP3, ACP1 | MAPK1 2423/4885LMNA 4643/4885KMT2A 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.